This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Oxygen Biotherapeutics Reports Successful Completion Of FDA Requested Immunocompetency Studies On Oxycyte®

Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT), is a development stage biomedical company currently focused on developing its perfluorocarbon-based intravenous oxygen carrier, Oxycyte ®, as a treatment for traumatic brain injury (TBI), stroke and other conditions where critical tissues are oxygen starved. Oxycyte is currently in Phase IIb clinical trials for TBI in Israel and Switzerland; however, the FDA has requested studies to explore the safety profile of Oxycyte with respect to immunocompetency as well as transient decreases in platelet numbers. The company announced today that with the successful completion of four important preclinical studies assessing Oxycyte’s potential effects on the immune system, OBI has moved several steps closer to addressing the questions posed by the FDA and demonstrating a favorable benefit to risk ratio for the product. These studies were funded as part of a $2.07 million cost reimbursement grant from the U.S. Army.

The use of any drug that lowers the body’s resistance to infection must be considered carefully, especially in the long-term hospitalization setting. A recent study reported in the journal, Clinical Microbiology and Infection, found that in TBI patients, the most common infection encountered is ventilator-associated pneumonia, followed by surgical site infections, urinary tract infections, pneumonia, catheter-associated bacteremias / blood stream infections and meningitis [Kourbeti, et al., Clin. Micrbiol. Infect., 19, 359-364, 2012]. Earlier this year, OBI obtained FDA buy-in for a series of studies designed to examine Oxycyte’s potential impact on immune function.

In experiments that used the Influenza virus to assess the overall health of the immune system, Oxycyte had only subtle effects on antibody production and did not adversely impact clearance of this common lung infection. Similarly, in a separate study examining the early phase response of the immune system, Oxycyte did not interfere with the efficient clearance of a Streptococcal pneumonia infection from the lung. Many TBI patients will experience as a result of being intubated one or more bouts of pneumonia; therefore, these results are important in that they provide evidence suggesting that Oxycyte does not compromise the patient’s ability to fight this infection often seen in the ICU. An additional experiment requested specifically by the FDA demonstrated that Oxycyte did not interfere with the ability of macrophages to identify and engulf bacteria and, thus, should have minimal effect on that clearance mechanism, which is associated with many common bacterial infections.

A fourth study was developed to test the potential immunomodulatory effects of Oxycyte in a Listeria model of systemic bacterial infection. This gram positive bacterium is extremely pathogenic and, if not controlled quickly, can progress to sepsis under conditions of immunosuppression. In our study, the administration of Oxycyte immediately prior to an injection of Listeria directly into the circulation resulted in a marked decrease in the animal’s ability to fend off this infection. It is important to note, however, that Listeria is not a bacterium commonly associated with TBI patients and was used in this study simply as a tool to assess immune function. Moreover, any blood stream infection occurring in a hospitalized patient will be treated aggressively regardless of what therapy that patient has received.

Stock quotes in this article: OXBT 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,262.56 +89.32 0.55%
S&P 500 1,842.98 +12.37 0.68%
NASDAQ 4,034.1610 +11.4670 0.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs